TTP Labtech acquires fluorescence lifetime technology
TTP Labtech has consolidated its position in the field of fluorescence lifetime (FLT) technology, having recently purchased assets from UK-based FLT company AssayMetrics.
The acquisition enhances TTP Labtech’s ameon system equipped with real-time decay curve analysis (RT-DCA), licensed from Fluorescence Innovations in the US. The product’s FLT reader technology provides a combination of speed, precision and data quality that can be readily exploited in high-throughput screen (HTS) workflows.
“The development of the ameon reader introduces an exciting new dimension to FLT technology, giving researchers a step-change in sample throughput and data quality,” said Dr Greg Gillispie, president of Fluorescence Innovations.
“Reception to ameon has been very positive,” added Dr Wayne Bowen, chief scientific officer of TTP Labtech, “with early feedback from beta-partners reporting superior tolerance to compound interference compared to established methodologies. Increasing access to relevant instrumentation is revealing the true potential of FLT for cost-critical assays to the screening community.”
Significant improvements in assay reagents and the availability of HTS-compatible readers are said to have propelled FLT technology to the forefront of cost-effective screening technologies.
CSL fellowships fund immunity research, AI-designed proteins
Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...
Leukaemia Foundation funds ongoing blood cancer research at UWA
The $3m in funding is understood to represent the single largest non-government investment in...
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
